Benitec Biopharma Long Term Debt 2014-2022 | BNTC

Benitec Biopharma long term debt from 2014 to 2022. Long term debt can be defined as the sum of all long term debt fields.
Benitec Biopharma Annual Long Term Debt
(Millions of US $)
2021 $
2020 $0
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
Benitec Biopharma Quarterly Long Term Debt
(Millions of US $)
2022-03-31 $1
2021-12-31 $1
2021-09-30 $1
2021-06-30
2021-03-31 $0
2020-12-31 $0
2020-09-30 $0
2020-06-30 $0
2020-03-31
2019-09-30
2017-09-30
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-06-30
2014-12-31
2014-06-30
2013-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.007B $0.000B
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $159.141B 9.65
GSK (GSK) United Kingdom $71.077B 8.53
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.276B 18.88
Biohaven Pharmaceutical Holding (BHVN) United States $10.581B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.200B 0.00
Arcus Biosciences (RCUS) United States $2.020B 39.44
Myovant Sciences (MYOV) United Kingdom $1.765B 0.00
Emergent Biosolutions (EBS) United States $1.521B 8.81
Zymeworks (ZYME) Canada $0.418B 0.00
Enzo Biochem (ENZ) United States $0.133B 0.00
Gelesis Holdings (GLS) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
Ambrx Biopharma (AMAM) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00